Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
Follow JANX
Janux Therapeutics, Inc. (JANX) EV/Sales
As of 16 October 2026, Janux Therapeutics, Inc. (JANX) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from −17.4× (March 2022) to 347× (May 2024); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −5.8× | — |
| FY2024 | 175× | 902.87% |
| FY2023 | 17.4× | (40.93%) |
| FY2022 | 29.5× | 20.32% |
| FY2021 | 24.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.2× | — |
| Mar 2026 | −6.0× | — |
| Sep 2025 | 27.2× | (84.43%) |
| Dec 2024 | 175× | 25.20% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMRA Galecto, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SVRA Savara Inc. compare | n/m |
| JANX Janux Therapeutics, Inc. | 2.8× |
| MNKD MannKind Corporation compare | 3.2× |
| IMTX Immatics N.V. compare | 13.2× |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 3,499× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)